Atlas Venture

Formed with Hummingbird assets, $187M, Callio brings trend to Singapore

Sticking with genetic targets validated by Alnylam and Ionis gave Intellia confidence to take CRISPR in vivo

With $70M series A, biotech backed by Arch, 5am and Atlas is developing a targeted steroid it believes will be safer, with lower and less frequent dosing

BioCentury’s roundup of translational innovations also includes targeting MSH3 to slow repeat expansion in Huntington’s; plus AAVs for kidney and T cells

Vertex competitor posts a first-day gain after an upsized offering; plus financings for Gh Research and Tectonic

Led by Orbimed, LAV, Boyu, biotech’s Asia ‘NewCo Model’ goes global

Companies founded in the West with Asian assets tell a story of China speed

Biotech VC Uciane Scarlett on getting the right mix of platform-to-asset

New targets start to outnumber incretins among start-ups exploring paths to deeper, higher-quality weight loss

Some firms are no longer making their latest funds their largest; others may follow